Anika Therapeutics Inc
NASDAQ:ANIK
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
203.6m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
200.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
38.4B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Anika Therapeutics Inc
Glance View
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 297 full-time employees. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Anika Therapeutics Inc is 54.7%, which is below its 3-year median of 61.3%.
Over the last 3 years, Anika Therapeutics Inc’s Gross Margin has decreased from 57.4% to 54.7%. During this period, it reached a low of 54.7% on Sep 30, 2025 and a high of 68.3% on Dec 31, 2023.
